Emerging Scientist Award 2024: Phage Therapies for Lung Infections | DDL Conference

Added:

Physiological Barriers, Resistance, and Delivery Challenges of Inhaled Phage Therapy

While phage therapy offers a promising alternative to combat multidrug-resistant lung infections, significant clinical and biological hurdles remain. A primary concern is the rapid evolution of bacterial resistance to specific bacteriophages, which can render treatment ineffective. Additionally, the human immune system poses a major obstacle; alveolar macrophages in the lungs can rapidly clear phages, and repeated administration may trigger neutralizing antibody responses. From a drug delivery perspective, the physical shear stress of nebulization and aerosolization can easily deactivate fragile viral particles, leading to inconsistent dosing. Finally, the highly specific nature of phages requires rapid, precise diagnostics to match the exact pathogen strain, a requirement that is often impractical in acute clinical settings compared to broad-spectrum antibiotics.

The biology of bacteriophages, specifically the lytic cycle, which allows these viruses to infect and destroy bacterial hosts.
The mechanisms of multidrug resistance (MDR) in bacterial pathogens and why traditional antibiotics are increasingly ineffective.
Fundamental principles of pulmonary drug delivery, including how inhaled particles are deposited in different regions of the respiratory tract.
Basic pulmonary physiology and lung immunology, particularly how the respiratory system clears foreign particles and biological entities.
Advanced formulation engineering techniques, such as spray-drying and lyophilization, used to stabilize biological entities like phages for inhalation.
The pharmacokinetics and pharmacodynamics (PK/PD) of self-replicating antimicrobials within the unique microenvironment of the lung.
Strategies for developing 'phage cocktails' and examining phage-antibiotic synergy to overcome bacterial resistance mechanisms.
The regulatory pathways, clinical trial designs, and safety challenges associated with approving inhaled phage therapies for human use.
136 views0likes38:55@theddlconferenceOriginal Release: 2025-01-20

This presentation introduces innovative engineering approaches for phage therapy and antibacterial protein delivery to combat multidrug-resistant bacterial infections. The research demonstrates that nebulizer selection significantly impacts phage stability during aerosolization, with vibrating mesh nebulizers being more process-friendly than jet nebulizers. Additionally, engineered endolysins with cationic peptide modifications can effectively target gram-negative bacteria, and combination therapies using depolymerases with antibiotics show synergistic effects in treating bacterial lung infections. These findings represent promising strategies for developing next-generation antibacterial treatments.